Onconova Therapeutics Overview
- Founded
- 1998
- Status
- Public
- Employees
- 12
- Stock Symbol
- ONTX
- Share Price
- $1.50
- (As of Monday Closing)
Onconova Therapeutics General Information
Description
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
Contact Information
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
- 375 Pheasant Run
- Newtown, PA 18940
- United States
+1 (267) 000-0000
Onconova Therapeutics Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.50 | $1.54 | $1.38 - $19.65 | $32.2M | 20.9M | 244K | -$1.25 |
Onconova Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 |
|---|---|---|---|---|
| EV | 35,882 | 61,951 | 33,772 | (10,411) |
| Revenue | 227 | 231 | 2,183 | 1,228 |
| EBITDA | (18,810) | (25,140) | (21,479) | (20,479) |
| Net Income | (18,828) | (25,157) | (21,503) | (20,573) |
| Total Assets | 59,990 | 19,986 | 23,674 | 17,923 |
| Total Debt | 0 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Onconova Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Onconova Therapeutics‘s full profile, request access.
Request a free trialOnconova Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat c
Biotechnology
Newtown, PA
12
As of 2020
00000
00000000
00000
00000000
ion ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit
0000 000000000
Lund, Sweden
00
As of 0000
000.00
0000
0000-00-00
00000000
000.00
00000000
t ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco labor
0000 000000000
London, United Kingdom
000
As of 0000
00000
0000
0000-00-00
00000000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialOnconova Therapeutics Competitors (76)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alligator Bioscience | Formerly VC-backed | Lund, Sweden | 00 | 000.00 | 00000000 | 000.00 |
| 00000000 000000000 | Formerly VC-backed | London, United Kingdom | 000 | 00000 | 00000000 | 00000 |
| 0000000 000 | Corporation | New York, NY | 00 | 00000 | 00000000 | 00000 |
| 000000000 00000000 | Formerly VC-backed | Cambridge, MA | 000 | 00.000 | 000000000 | 00.000 |
| 000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000000 | 00.000 |
Onconova Therapeutics Patents
Onconova Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3880206-A1 | 8-cyclopentyl-7-oxo-2-(4-piperazin-1-yl-phenylamino)-7, 8-dihydro-pyrido [2,3-d]pyrimidine-6-carbonitrile and uses thereof in treating proliferative disorders | Pending | 12-Nov-2018 | 0000000000 | |
| US-10098862-B1 | Formulations with enhanced stability and bioavailability for administration of (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones | Active | 13-Apr-2017 | 0000000000 | |
| AU-2018253291-A1 | Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability | Pending | 13-Apr-2017 | 0000000000 | |
| JP-2020516665-A | (e)-2,6-dialkoxystyryl 4-substituted benzylsulfone formulations with improved stability and bioavailability for administration | Pending | 13-Apr-2017 | 00000000 | |
| US-20180296513-A1 | Formulations with enhanced stability and bioavailability for administantion of (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones | Granted | 13-Apr-2017 | A61K31/196 |
Onconova Therapeutics Executive Team (15)
Onconova Therapeutics Board Members (16)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alan Williamson | Onconova Therapeutics | Board Member | 000 0000 |
| Jack Stover | Self | Board Member | 000 0000 |
| James Marino JD | Self | Chairman & Board Member | 000 0000 |
| Jerome Groopman MD | Self | Board Member | 000 0000 |
| Mary Shoemaker | Onconova Therapeutics | Board Member | 000 0000 |
Onconova Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialOnconova Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Onconova Therapeutics‘s full profile, request access.
Request a free trial